AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
AbbVie (ABBV) raised its dividend 5.5% to $1.73 despite a 36% drop in Humira sales. Skyrizi and Rinvoq offset losses, but Skyrizi faces patent expiry in 2033. The company generated $17.8B in free cash flow, covering dividends. ABBV's $10.9B Apogee acquisition adds leverage but management aims to reduce it within three years.
How this was made
The 30-second read
Why it matters
The dividend hike signals confidence in cash flow, but the 36% sales drop and added leverage raise concerns about sustainable earnings.
Market read
Income‑focused investors may be drawn to the higher dividend, while growth‑oriented investors may shy away due to revenue erosion.
What to watch
Potential upside from Skyrizi and Rinvoq growth and the upcoming Apogee acquisition synergies could mitigate short‑term earnings drag.
Background
AbbVie (NYSE:ABBV) is a leading immunology and oncology drugmaker facing a patent cliff on its flagship product Humira.
Ticker impact
AbbVie announced a 5.5% quarterly dividend increase to $1.73 while reporting a 36% drop in Humira sales and detailing the $10.9B Apogee acquisition.
Potential short‑term upside from dividend news, offset by medium‑term downside from revenue erosion and leverage increase.
The dividend hike is a positive corporate action, yet the magnitude of the sales collapse and new debt suggest earnings pressure.
Market effects
Biopharma dividend yields may become more attractive as growth slows, prompting sector rotation toward income stocks.
U.S. large‑cap healthcare index could see modest pressure from AbbVie's revenue decline.
Limited; primarily affects U.S. investors focused on dividend income.
Counterpoint
Despite the dividend increase, the underlying revenue weakness may signal a longer‑term decline, suggesting a short position.
Key entities
- CompanyAbbVie
U.S. biopharma company reporting dividend increase and sales decline.
- CompanyApogee Therapeutics
Target of AbbVie's $10.9B acquisition.